A Study of HRS-4729 Injection in Participants With Type 2 Diabetes
NCT07843862 on ClinicalTrials.gov · last registry update 2026-09-28
An unusually large phase 2: 240 participants, more than double the 110 typical for the stage. Due to report April 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: Change From Baseline in HbA1c. Sponsors move these dates routinely; any movement since this site started watching is listed below. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- NOT_YET_RECRUITING
- Phase
- P2
- Drug
- mazdutide
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
- Sponsor type
- Industry
- Enrollment
- 240
- Started
- 2026-10
- Primary completion
- 2027-04 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-28 | First seen in registry | Registered as NOT_YET_RECRUITING, P2 |
Primary outcome
Change From Baseline in HbA1c
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.